Guided Therapeutics bullish on cervical scan despite second FDA knock-back
This article was originally published in Clinica
Executive Summary
Guided Therapeutics’ share price has plunged again after it was hit by a second FDA rejection of its flagship LuViva noninvasive cervical cancer scanning technology. Although a blow to the company, the agency’s not-approvable letter is potentially good news for the producers of rival cervical cancer screening techniques such as Pap smears and human papillomavirus (HPV) testing, including Hologic and Qiagen.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.